319 related articles for article (PubMed ID: 31470883)
1. Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway.
Islam SS; Aboussekhra A
J Exp Clin Cancer Res; 2019 Aug; 38(1):382. PubMed ID: 31470883
[TBL] [Abstract][Full Text] [Related]
2. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
[TBL] [Abstract][Full Text] [Related]
3. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
6. MDM2 inhibition improves cisplatin-induced renal injury in mice via inactivation of Notch/hes1 signaling pathway.
Luo X; Zhang L; Han GD; Lu P; Zhang Y
Hum Exp Toxicol; 2021 Feb; 40(2):369-379. PubMed ID: 32856486
[TBL] [Abstract][Full Text] [Related]
7. Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1.
Tyagi A; Vishnoi K; Mahata S; Verma G; Srivastava Y; Masaldan S; Roy BG; Bharti AC; Das BC
Clin Cancer Res; 2016 Aug; 22(16):4170-84. PubMed ID: 26988248
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
9. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
11. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
12. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
McAuliffe SM; Morgan SL; Wyant GA; Tran LT; Muto KW; Chen YS; Chin KT; Partridge JC; Poole BB; Cheng KH; Daggett J; Cullen K; Kantoff E; Hasselbatt K; Berkowitz J; Muto MG; Berkowitz RS; Aster JC; Matulonis UA; Dinulescu DM
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):E2939-48. PubMed ID: 23019585
[TBL] [Abstract][Full Text] [Related]
13. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.
Kang HG; Kim DH; Kim SJ; Cho Y; Jung J; Jang W; Chun KH
Oncotarget; 2016 Oct; 7(42):68229-68241. PubMed ID: 27626163
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
17. STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway.
Jin L; Vu T; Yuan G; Datta PK
Cancer Res; 2017 Oct; 77(20):5464-5478. PubMed ID: 28827371
[TBL] [Abstract][Full Text] [Related]
18. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces stemness in ovarian cancer.
Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
[TBL] [Abstract][Full Text] [Related]
20. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
